Claire is a leading practitioner at PwC Deals focusing on private equity and pharma and life sciences companies in commercial due diligences, integrations, and growth strategies. Within the area of pharma and life sciences she has deep expertise in gene therapy, rare diseases, women's health, vaccines, oncology, generics, and primary care on the pharma side.
Claire has authored various publications (through BCG’s Bruce Henderson Institute) including topics on how corporations (and leaders) need a new adaptive style of strategy, given the rate of change and technological innovation impacting many industries as well as on how truly sustainable businesses are those that align the social, environmental, and business vectors.
Before joining Strategy&, she worked at Credit Suisse in equity research and credit derivatives as well as in the Chancellor's Office of the NYC Department of Education.
Claire holds an MBA from Harvard Business School with honors and a MPA from Harvard Kennedy School, where she was a George Fellow. She further received a Bachelor in economics and international studies from Yale University with distinction and studied at Oxford.